PATH-3 Technology exhibits long-term tolerability in treatment of facial dyschromia

A topical formulation with PATH-3 Technology demonstrated long-term effects and tolerability in the treatment of facial dyschromia, according to a study.
“Dyschromia continues to be a challenging cutaneous condition to treat, which has been complicated by the complex pathways involved and the nuances of individual cases,” Jordan V. Wang, MD, MBE, MBA, FAAD, of the Laser & Skin Surgery Center of New York, and colleagues wrote.
Building on the 12-week study that these researchers conducted comparing A-Luminate (AL; Alastin Skincare) brightening serum, a novel, topical formulation

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart